|
1
|
Rodríguez-Galindo C, Liu T, Krasin MJ, Wu
J, Billups CA, Daw NC, Spunt SL, Rao BN, Santana VM and Navid F:
Analysis of prognostic factors in ewing sarcoma family of tumors:
Review of St. Jude Children's Research Hospital studies. Cancer.
110:375–384. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Granowetter L, Womer R, Devidas M, Krailo
M, Wang C, Bernstein M, Marina N, Leavey P, Gebhardt M, Healey J,
et al: Dose-intensified compared with standard chemotherapy for
nonmetastatic Ewing sarcoma family of tumors: A Children's Oncology
Group Study. J Clin Oncol. 27:2536–2541. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kolb EA, Kushner BH, Gorlick R, Laverdiere
C, Healey JH, LaQuaglia MP, Huvos AG, Qin J, Vu HT, Wexler L, et
al: Long-term event-free survival after intensive chemotherapy for
Ewing's family of tumors in children and young adults. J Clin
Oncol. 21:3423–3430. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Barker LM, Pendergrass TW, Sanders JE and
Hawkins DS: Survival after recurrence of Ewing's sarcoma family of
tumors. J Clin Oncol. 23:4354–4362. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Walenta S and Mueller-Klieser WF: Lactate:
Mirror and motor of tumor malignancy. Semin Radiat Oncol.
14:267–274. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Albain KS, Crowley JJ, LeBlanc M and
Livingston RB: Determinants of improved outcome in small-cell lung
cancer: An analysis of the 2,580-patient Southwest Oncology Group
data base. J Clin Oncol. 8:1563–1574. 1990.PubMed/NCBI
|
|
7
|
Tas F, Aykan F, Alici S, Kaytan E, Aydiner
A and Topuz E: Prognostic factors in pancreatic carcinoma: Serum
LDH levels predict survival in metastatic disease. Am J Clin Oncol.
24:547–550. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Smaletz O, Scher HI, Small EJ, Verbel DA,
McMillan A, Regan K, Kelly WK and Kattan MW: Nomogram for overall
survival of patients with progressive metastatic prostate cancer
after castration. J Clin Oncol. 20:3972–3982. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Terpos E, Katodritou E, Roussou M, Pouli
A, Michalis E, Delimpasi S, Parcharidou A, Kartasis Z, Zomas A,
Symeonidis A, et al: High serum lactate dehydrogenase adds
prognostic value to the international myeloma staging system even
in the era of novel agents. Eur J Haematol. 85:114–119.
2010.PubMed/NCBI
|
|
10
|
Chen J, Sun MX, Hua YQ and Cai ZD:
Prognostic significance of serum lactate dehydrogenase level in
osteosarcoma: A meta-analysis. J Cancer Res Clin Oncol.
140:1205–1210. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Casadei R, Magnani M, Biagini R and
Mercuri M: Prognostic factors in Ewing's sarcoma of the foot. Clin
Orthop Relat Res. 230–238. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Tierney JF, Stewart LA, Ghersi D, Burdett
S and Sydes MR: Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials. 8:162007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Parmar MK, Torri V and Stewart L:
Extracting summary statistics to perform meta-analyses of the
published literature for survival endpoints. Stat Med.
17:2815–2834. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Slim K, Nini E, Forestier D, Kwiatkowski
F, Panis Y and Chipponi J: Methodological index for non-randomized
studies (minors): Development and validation of a new instrument.
ANZ J Surg. 73:712–716. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mantel N and Haenszel W: Statistical
aspects of the analysis of data from retrospective studies of
disease. J Natl Cancer Inst. 22:719–748. 1959.PubMed/NCBI
|
|
16
|
Egger M, Smith G Davey, Schneider M and
Minder C: Bias in meta-analysis detected by a simple, graphical
test. BMJ. 315:629–634. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aparicio J, Munárriz B, Pastor M, Vera FJ,
Castel V, Aparisi F, Montalar J, Badal MD, Gómez-Codina J and
Herranz C: Long-term follow-up and prognostic factors in Ewing's
sarcoma. A multivariate analysis of 116 patients from a single
institution. Oncology. 55:20–26. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bacci G, Longhi A, Ferrari S, Mercuri M,
Versari M and Bertoni F: Prognostic factors in non-metastatic
Ewing's sarcoma tumor of bone: An analysis of 579 patients treated
at a single institution with adjuvant or neoadjuvant chemotherapy
between 1972 and 1998. Acta Oncol. 45:469–475. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Biswas B, Shukla NK, Deo SV, Agarwala S,
Sharma DN, Vishnubhatla S and Bakhshi S: Evaluation of outcome and
prognostic factors in extraosseous Ewing sarcoma. Pediatr Blood
Cancer. 61:1925–1931. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
da Costa CM, Lopes A and de Camargo B: A
simple cost-effective lactate dehydrogenase level measurement can
stratify patients with Ewing's tumor into low and high risk. Ann
Oncol. 14:6562003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Farley FA, Healey JH, Caparros-Sison B,
Godbold J, Lane JM and Glasser DB: Lactase dehydrogenase as a tumor
marker for recurrent disease in Ewing's sarcoma. Cancer.
59:1245–1248. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Glaubiger DL, Makuch R, Schwarz J, Levine
AS and Johnson RE: Determination of prognostic factors and their
influence on therapeutic results in patients with Ewing's sarcoma.
Cancer. 45:2213–2219. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Leavey PJ, Mascarenhas L, Marina N, Chen
Z, Krailo M, Miser J, Brown K, Tarbell N, Bernstein ML, Granowetter
L, et al: Prognostic factors for patients with Ewing sarcoma (EWS)
at first recurrence following multi-modality therapy: A report from
the Children's Oncology Group. Pediatr Blood Cancer. 51:334–338.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Luksch R, Sampietro G, Collini P, Boracchi
P, Massimino M, Lombardi F, Gandola L, Giardini R, Fossati-Bellani
F, Migliorini L, et al: Prognostic value of clinicopathologic
characteristics including neuroectodermal differentiation in
osseous Ewing's sarcoma family of tumors in children. Tumori.
85:101–107. 1999.PubMed/NCBI
|
|
25
|
Tural D, Mandel N Molinas, Dervisoglu S,
Dincbas F Oner, Koca S, Oksuz D Colpan, Kantarci F, Turna H,
Selcukbiricik F and Hiz M: Extraskeletal Ewing's sarcoma family of
tumors in adults: Prognostic factors and clinical outcome. Jpn J
Clin Oncol. 42:420–426. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Grunewald TG, Ranft A, Esposito I, da
Silva-Buttkus P, Aichler M, Baumhoer D, Schaefer KL, Ottaviano L,
Poremba C, Jundt G, et al: High STEAP1 expression is associated
with improved outcome of Ewing's sarcoma patients. Ann Oncol.
23:2185–2190. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hingorani P, Dickman P, Garcia-Filion P,
White-Collins A, Kolb EA and Azorsa DO: BIRC5 expression is a poor
prognostic marker in Ewing sarcoma. Pediatr Blood Cancer. 60:35–40.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Haga A, Ogawara Y, Kubota D, Kitabayashi
I, Murakami Y and Kondo T: Interactomic approach for evaluating
nucleophosmin-binding proteins as biomarkers for Ewing's sarcoma.
Electrophoresis. 34:1670–1678. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Na KY, Kim HS, Jung WW, Sung JY, Kalil RK,
Kim YW and Park YK: CXCL16 and CXCR6 in Ewing sarcoma family tumor.
Hum Pathol. 45:753–760. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shukla N, Schiffman J, Reed D, Davis IJ,
Womer RB, Lessnick SL and Lawlor ER: COG Ewing Sarcoma Biology
Committee: Biomarkers in Ewing Sarcoma: The promise and challenge
of personalized medicine. A Report from the Children's Oncology
Group. Front Oncol. 3:1412013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brereton HD, Simon R and Pomeroy TC:
Pretreatment serum lactate dehydrogenase predicting metastatic
spread in Ewing's sarcoma. Ann Intern Med. 83:352–354. 1975.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pomeroy TC and Johnson RE: Combined
modality therapy of Ewing's sarcoma. Cancer. 35:36–47. 1975.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Crane CA, Austgen K, Haberthur K, Hofmann
C, Moyes KW, Avanesyan L, Fong L, Campbell MJ, Cooper S, Oakes SA,
et al: Immune evasion mediated by tumor-derived lactate
dehydrogenase induction of NKG2D ligands on myeloid cells in
glioblastoma patients. Proc Natl Acad Sci USA. 111:12823–12828.
2014. View Article : Google Scholar : PubMed/NCBI
|
